An illustration · invented records · this source is real
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial
Yang SX, Yu J, Wang M, et al. (2024). Journal of the National Comprehensive Cancer Network. PubMed 39019060 · DOI 10.6004/jnccn.2024.7008 · PubMed record
What kind of source: Long-term follow-up analysis of TAILORx. Where it sits in the summary: Still being studied. Back to the summary
What it says, in plain language
With follow-up reaching about eleven and a half years, the score remained strongly associated with breast-cancer mortality and recurrence, but a weaker one for overall survival.
Source access: this note uses the published abstract, linked above. The full article was not available for this review and is not included in the folder.
The exact words we relied on
“Event rates for BCSS, OS, RFI, and DFS were 1.7%, 5.2%, 5.6%, and 12.6%, respectively, by up to 11.6 years of follow-up.” — PMID:39019060, Abstract, Results
“RS is an independent measure for BCSS and recurrence prognoses relative to OS in early-stage breast cancer.” — PMID:39019060, Abstract, Conclusions
How these quotes were checked
Follow the passage links above to the included paper or public source record.
Abstract only. The quotes above come from the paper’s published abstract as held in the PubMed record. They were checked by exact string match against the PubMed record cached on 2026-09-08. This note is limited to the abstract; the full article was not read.
Limits of this source
This is about how well the score predicts outcomes, not about whether chemotherapy changes them. Abstract only.
Review
Reviewed by Sarah Kiselycznyk · September 10, 2026. Review scope and verification method: How we researched this.